Skip to main content
TipRanks
Go Ultimate75% OFF

Taidoc Technology Corporation (4736) AI Stock Analysis

TW:4736

Taidoc Technology Corporation

(TWSE:4736)

Select Model
Rating:70Outperform
Price Target:TWD 139.00â–²(6.92% Upside)
Action:initiatedcoverage
Date:11/09/26

Attractive valuation and strong balance sheet are the main positives, tempered by revenue contraction, cash flow volatility, and mixed technical signals.

Positive Factors
Conservative Balance SheetLow and stable leverage, together with growing equity, gives Taidoc financial flexibility to support operations and pursue opportunities without excessive balance-sheet strain. This conservative structure should improve resilience through softer demand and reduce the risk that debt limits future capital allocation.
Negative Factors
Multi-Year Revenue DeclineSeveral years of falling revenue point to a persistent demand or product-mix challenge rather than a single-period fluctuation. Continued contraction can reduce scale benefits, limit reinvestment capacity, and make future profit growth increasingly dependent on cost control instead of expanding market demand.

Taidoc Technology Corporation (4736) vs. SPDR S&P 500 ETF (SPY)

-10%-5%0%5%10%15%20%25%TW:4736+20.33%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 13.36B
Dividend Yield
3.90%
Average Volume (3M)
296.00K
Price to Earnings (P/E)
5.0
Beta (1Y)
0.26
Revenue Growth
-0.47%
EPS Growth
45.76%
Country
TW
Employees
654
Sector
General
Sector Strength
55
Industry
Medical - Devices

Taidoc Technology Corporation Business Overview & Revenue Model

Company Description

TaiDoc Technology Corporation, established in 1998 and based in New Taipei City, Taiwan, is a leading global producer and distributor of a wide array of medical devices. The company's comprehensive product catalog features advanced in vitro diagnosti...

Taidoc Technology Corporation Financial Statement Overview

Summary

Strong balance sheet with minimal debt and steady ROE, supported by resilient net margins above 34 percent, offset by revenue decline since 2022 and volatile cash flows.

Income Statement

65Positive

Balance Sheet

84Very Positive

Cash Flow

52Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.23B4.20B4.64B4.81B9.63B6.49B
Gross Profit1.80B1.93B2.05B2.07B5.65B3.21B
EBITDA930.01M1.10B1.65B1.19B4.61B2.74B
Net Income2.56B1.44B1.16B1.02B3.38B1.97B
Balance Sheet
Total Assets14.38B12.78B12.24B11.91B12.90B10.52B
Cash, Cash Equivalents and Short-Term Investments6.26B5.23B4.94B4.73B5.03B3.08B
Total Debt941.14M1.16B1.05B1.09B636.31M1.26B
Total Liabilities3.02B2.66B2.72B2.65B2.91B2.89B
Stockholders Equity11.01B9.79B9.09B8.90B9.67B7.39B
Cash Flow
Free Cash Flow780.11M602.17M-536.61M1.06B2.70B1.59B
Operating Cash Flow1.05B853.39M-181.37M1.17B3.21B1.92B
Investing Cash Flow152.35M-298.12M-52.38M129.57M-573.83M-675.07M
Financing Cash Flow-1.20B-895.55M-977.50M-1.46B-1.77B-604.80M

Taidoc Technology Corporation Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4736 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:4736TW:473670OutperformTWD 13.26B5.04―3.90%-0.47%45.76%
TW:6667TW:666764NeutralTWD 12.62B12.58―4.56%28.55%55.47%
TW:4104TW:410461NeutralTWD 13.58B14.58―5.97%11.09%7.11%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%200%400%600%800%TW:4736TW:4104TW:6667TW:6748TW:7780TW:7853Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4736 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4736Taidoc Technology Corporation130.0021.5319.84%
TW:4104Excelsior Medical Co., Ltd.72.00-5.81-7.47%
TW:6667Trusval Technology Co., Ltd.249.0027.6912.51%
TW:6748ACRO Biomedical Co., Ltd.169.50111.12190.35%
TW:7780Daiken Biomedical Co., Ltd.15.10-2.15-12.45%
TW:7853Cheng Mei Instrument Technology Co., Ltd.332.50266.00400.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026